Dishman Pharma, the top gainer on the BSE currently, breached the 20% UC at Rs.278.20, a new 52-week high too. Some 5,57,771 pending buy orders remained at this UC.

With companies getting bad news almost always from the US FDA, this rare piece of good news from Dishman was celebrated by the market with gusto.

The company has received the US FDA approval for its cancer drug Zejula Capsules, for Tesaro Inc.

The company has said, “There are several products pending for approval and will be in talks with Tisaro for further action. It is tough to predict revenue potential from Zejula approval."